NASDAQ:PETX - Aratana Therapeutics Stock Price, Price Target & More

$4.97 -0.24 (-4.61 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$5.21
Today's Range$4.92 - $5.19
52-Week Range$3.67 - $7.67
Volume413,442 shs
Average Volume493,959 shs
Market Capitalization$237.53 million
P/E Ratio-5.12
Dividend YieldN/A
Beta2.91

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Debt-to-Equity Ratio0.24%
Current Ratio2.40%
Quick Ratio2.02%

Price-To-Earnings

Trailing P/E Ratio-5.12
Forward P/E Ratio-8.15
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.57 million
Price / Sales8.91
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book2.67

Profitability

EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-185.78%
Return on Equity-45.15%
Return on Assets-28.23%

Miscellaneous

Employees85
Outstanding Shares45,850,000

How to Become a New Pot Stock Millionaire

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) released its earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biopharmaceutical company had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative return on equity of 45.15% and a negative net margin of 185.78%. View Aratana Therapeutics' Earnings History.

When is Aratana Therapeutics' next earnings date?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Aratana Therapeutics.

What price target have analysts set for PETX?

6 brokerages have issued 12-month price objectives for Aratana Therapeutics' stock. Their forecasts range from $8.00 to $10.00. On average, they anticipate Aratana Therapeutics' share price to reach $8.8333 in the next year. View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (3/7/2018)
  • 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Wendy L. Yarno, Chairman of the Board (Age 63)
  • Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
  • Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
  • Brent Standridge, Chief Operating Officer (Age 58)
  • Ernst Heinen Ph.D., Chief Development Officer (Age 52)
  • Laura A. Brege, Independent Director (Age 59)
  • David L. Brinkley, Independent Director (Age 57)
  • Robert Benthall Gerber Jr., Independent Director (Age 52)
  • Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
  • Merilee Raines, Independent Director (Age 61)

Has Aratana Therapeutics been receiving favorable news coverage?

Press coverage about PETX stock has been trending somewhat positive on Thursday, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $4.97.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $237.53 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (PETX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aratana Therapeutics (NASDAQ:PETX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Aratana Therapeutics in the last 12 months. Their average twelve-month price target is $8.8333, suggesting that the stock has a possible upside of 77.73%. The high price target for PETX is $10.00 and the low price target for PETX is $8.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.832.673.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.8333$8.50$8.75$8.3333
Price Target Upside: 77.73% upside110.40% upside67.62% upside55.18% upside

Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History

Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018Stifel NicolausUpgradeHold -> Buy$6.00 -> $8.00HighView Rating Details
3/19/2018HC WainwrightSet Price TargetBuy$10.00LowView Rating Details
3/16/2018Credit Suisse GroupReiterated RatingOutperform -> Outperform$9.00 -> $8.00LowView Rating Details
3/12/2018CL KingUpgradeNeutral -> Buy$8.00HighView Rating Details
11/16/2017Jefferies GroupSet Price TargetBuy$9.00N/AView Rating Details
8/25/2017Lake Street CapitalLower Price TargetBuy -> Buy$15.00 -> $10.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016BarclaysLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Aratana Therapeutics (NASDAQ:PETX) Earnings History and Estimates Chart

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.57)
2019 EPS Consensus Estimate: $0.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.20)($0.18)($0.19)
Q2 20182($0.17)($0.15)($0.16)
Q3 20182($0.14)($0.14)($0.14)
Q4 20182($0.11)($0.04)($0.08)
Q1 20192($0.10)$0.25$0.08
Q2 20192($0.03)$0.02($0.01)
Q3 20191($0.01)($0.01)($0.01)
Q4 20191$0.01$0.01$0.01

Aratana Therapeutics (NASDAQ PETX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.19)N/AView Earnings Details
3/13/2018Q4 2017($0.23)($0.19)$5.72 million$10.46 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.21)$6.47 million$6.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40$0.12 millionViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aratana Therapeutics (NASDAQ:PETX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 66.65%
Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)
Insider Trading History for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2018Peter Steven StCEOSell19,367$4.77$92,380.59672,259View SEC Filing  
1/11/2018Craig A ToomanInsiderSell30,000$5.27$158,100.0075,024View SEC Filing  
12/1/2017Healthcare Master Fun BroadfinMajor ShareholderSell890,516$5.70$5,075,941.20View SEC Filing  
11/29/2017Healthcare Master Fun BroadfinMajor ShareholderSell116,516$6.53$760,849.48View SEC Filing  
11/10/2017Peter Steven StInsiderSell50,000$7.00$350,000.00529,359View SEC Filing  
10/2/2017Peter Steven StInsiderSell50,000$6.24$312,000.00View SEC Filing  
9/25/2017Brent StandridgeCOOSell10,000$6.11$61,100.0070,267View SEC Filing  
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00130,994View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00582,693View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00632,693View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00592,793View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00115,494View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.0072,424View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00642,793View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00127,503View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00717,793View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00125,494View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16102,424View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.4069,980View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.0073,600View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.0095,294View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aratana Therapeutics (NASDAQ PETX) News Headlines

Source:
DateHeadline
Zacks Investment Research Lowers Aratana Therapeutics (PETX) to HoldZacks Investment Research Lowers Aratana Therapeutics (PETX) to Hold
www.americanbankingnews.com - April 18 at 5:18 PM
Aratana Therapeutics (PETX) Downgraded by BidaskClub to HoldAratana Therapeutics (PETX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 17 at 1:27 PM
Aratana Therapeutics Inc (PETX) Receives Average Recommendation of "Hold" from AnalystsAratana Therapeutics Inc (PETX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 1:40 PM
Aratana Therapeutics (PETX) Stock Rating Lowered by ValuEngineAratana Therapeutics (PETX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 15 at 9:51 AM
Aratana Therapeutics (PETX) Downgraded by BidaskClub to "Sell"Aratana Therapeutics (PETX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 14 at 4:46 PM
Aratana Therapeutics (PETX) Rating Lowered to Strong Sell at BidaskClubAratana Therapeutics (PETX) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 12 at 6:14 PM
Aratana Therapeutics to Report First Quarter 2018 Financial ResultsAratana Therapeutics to Report First Quarter 2018 Financial Results
finance.yahoo.com - April 12 at 9:53 AM
Engaged Capital Nominates Three to ARATANA THERAPEUTICs (PETX) BoardEngaged Capital Nominates Three to ARATANA THERAPEUTIC's (PETX) Board
www.streetinsider.com - April 6 at 9:24 AM
$6.06 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter$6.06 Million in Sales Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - April 6 at 3:56 AM
Aratana Therapeutics (PETX) Confirms Receipt of Board Nominations from Engaged CapitalAratana Therapeutics (PETX) Confirms Receipt of Board Nominations from Engaged Capital
www.streetinsider.com - April 5 at 4:43 PM
-$0.18 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter-$0.18 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - April 4 at 9:33 AM
Aratana Therapeutics (PETX) Stock Rating Upgraded by Zacks Investment ResearchAratana Therapeutics (PETX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 8:52 PM
Aratana Therapeutics (PETX) and The Competition Financial ContrastAratana Therapeutics (PETX) and The Competition Financial Contrast
www.americanbankingnews.com - March 31 at 5:10 PM
Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in SessionAratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session
finance.yahoo.com - March 28 at 9:20 AM
Pre-Open Movers 03/27: (ATRS) (PETX) (RHT) Higher; (LFIN) (GERN) (OSTK) Lower (more...)Pre-Open Movers 03/27: (ATRS) (PETX) (RHT) Higher; (LFIN) (GERN) (OSTK) Lower (more...)
www.streetinsider.com - March 27 at 4:40 PM
Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In UpgradePet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade
finance.yahoo.com - March 27 at 4:40 PM
Aratana Therapeutics (PETX) Lifted to "Buy" at Stifel NicolausAratana Therapeutics (PETX) Lifted to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - March 27 at 10:07 AM
Aratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from BrokeragesAratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 21 at 1:44 PM
Aratana Therapeutics (PETX) Given a $10.00 Price Target at HC WainwrightAratana Therapeutics (PETX) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 19 at 5:02 PM
Q1 2018 Earnings Forecast for Aratana Therapeutics Inc Issued By William Blair (PETX)Q1 2018 Earnings Forecast for Aratana Therapeutics Inc Issued By William Blair (PETX)
www.americanbankingnews.com - March 19 at 1:52 AM
Edited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:02 AM
Aratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.20 Per ShareAratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 18 at 8:46 AM
Aratana Therapeutics (PETX) PT Lowered to $8.00Aratana Therapeutics (PETX) PT Lowered to $8.00
www.americanbankingnews.com - March 16 at 11:34 AM
Aratana Therapeutics (PETX) CEO Steven St. Peter on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAratana Therapeutics' (PETX) CEO Steven St. Peter on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 6:10 PM
Aratana raises $11.7M despite aborted stock offeringAratana raises $11.7M despite aborted stock offering
finance.yahoo.com - March 14 at 6:10 PM
Aratana Therapeutics Q4 Earnings PreviewAratana Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 14 at 9:55 AM
Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsAratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 14 at 9:55 AM
When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)?
finance.yahoo.com - March 13 at 9:18 AM
Aratana Therapeutics (PETX) Upgraded by CL King to BuyAratana Therapeutics (PETX) Upgraded by CL King to Buy
www.americanbankingnews.com - March 12 at 9:22 PM
Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?Is a Surprise Coming for Aratana Therapeutics (PETX) This Earnings Season?
www.zacks.com - March 9 at 9:30 AM
Aratana Therapeutics (PETX) Lifted to Hold at Zacks Investment ResearchAratana Therapeutics (PETX) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 7 at 11:33 AM
General American Investors Co. Inc. Grows Stake in Aratana Therapeutics Inc (PETX)General American Investors Co. Inc. Grows Stake in Aratana Therapeutics Inc (PETX)
www.americanbankingnews.com - March 6 at 9:04 AM
AWM Investment Company Inc. Has $7.77 Million Position in Aratana Therapeutics Inc (PETX)AWM Investment Company Inc. Has $7.77 Million Position in Aratana Therapeutics Inc (PETX)
www.americanbankingnews.com - March 6 at 4:44 AM
Aratana Therapeutics (PETX) Scheduled to Post Quarterly Earnings on MondayAratana Therapeutics (PETX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Aratana Therapeutics (PETX) Expands Pipeline - StreetInsider.comAratana Therapeutics (PETX) Expands Pipeline - StreetInsider.com
www.streetinsider.com - March 3 at 5:33 PM
Zacks: Analysts Anticipate Aratana Therapeutics Inc (PETX) Will Announce Quarterly Sales of $5.72 MillionZacks: Analysts Anticipate Aratana Therapeutics Inc (PETX) Will Announce Quarterly Sales of $5.72 Million
www.americanbankingnews.com - March 3 at 1:22 PM
Aratana builds pet drug pipeline by buying rights from Japanese companyAratana builds pet drug pipeline by buying rights from Japanese company
finance.yahoo.com - March 2 at 5:25 PM
Aratana Therapeutics (PETX) Expands PipelineAratana Therapeutics (PETX) Expands Pipeline
www.streetinsider.com - March 2 at 9:01 AM
Aratana Therapeutics to Participate at Upcoming Investment ConferencesAratana Therapeutics to Participate at Upcoming Investment Conferences
finance.yahoo.com - March 2 at 9:01 AM
Aratana Therapeutics Inc (PETX) Stake Lessened by Broadfin Capital LLCAratana Therapeutics Inc (PETX) Stake Lessened by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Aratana Therapeutics Expands Therapeutic Candidate PipelineAratana Therapeutics Expands Therapeutic Candidate Pipeline
finance.yahoo.com - March 1 at 8:53 AM
-$0.23 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter-$0.23 Earnings Per Share Expected for Aratana Therapeutics Inc (PETX) This Quarter
www.americanbankingnews.com - March 1 at 5:08 AM
Aratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from AnalystsAratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 1:32 PM
Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana TherapeuticsTechnical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics
www.bizjournals.com - February 23 at 9:04 AM
Aratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial ResultsAratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 13 at 9:30 AM
Aratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per ShareAratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 12 at 1:20 PM
Aratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 SharesAratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 Shares
www.americanbankingnews.com - February 1 at 6:28 PM
Aratana Therapeutics Inc (PETX) Receives Consensus Rating of "Hold" from BrokeragesAratana Therapeutics Inc (PETX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 1:32 PM
Zacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 MillionZacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 Million
www.americanbankingnews.com - January 28 at 4:12 AM
Aratana Therapeutics (PETX) Lowered to Sell at Zacks Investment ResearchAratana Therapeutics (PETX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 17 at 11:26 AM

SEC Filings

Aratana Therapeutics (NASDAQ:PETX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aratana Therapeutics (NASDAQ PETX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.